ASX:TLXBiotechs
Telix Targets Prostate And Brain Cancer Growth With AI And Glioma Push
Telix Pharmaceuticals (ASX:TLX) has entered an AI research collaboration with University Hospital Essen focused on PSMA-PET imaging in prostate cancer.
The partnership will use Telix’s AI tools and the PROMISE-PET registry to build prognostic models for prostate cancer imaging.
Telix has also submitted a European marketing authorization application for TLX101-Px, an advanced glioma imaging candidate.
The glioma submission aims to address the need for more consistent, high-quality brain...